Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen < 0.01 ng/mL; or
Prostate specific antigen (PSA) < 20, within 6 months of study entry\r\n* Participants who are currently receiving dutasteride (or have received it within the last 90 days) or finasteride (or have received it within the last 30 days) must have a PSA of =< 10
Prostate-specific antigen (PSA) progression: minimum of 2 rising values (3 measurements) obtained a minimum of 7 days apart with the last result being at least >/= 1.0 ng/mL;
Prostate specific antigen (PSA) =< 80 ng/ml, obtained within 3 months
Most recent prostate specific antigen (PSA) within 60 days of enrollment
Prostate specific antigen (PSA) =< 10 ng/mL within 90 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy
Prostate specific antigen (PSA) >= 0.2 ng/ml that is confirmed with a second PSA measurement
PSA values < 20 ng/ml within 90 days prior to registration, done either prior to prostate biopsy or at least 21 days after prostate biopsy
Prostate specific antigen (PSA) =< 20 ng/dL
Prostate specific antigen (PSA) of less than 10 ng/ml
No distant metastases on bone scan (only necessary if prostate specific antigen [PSA] >= 10 ng/ml and/or Gleason score >= 7)
Serum prostate specific antigen (PSA) level < 20 ng/ml
Prostate-specific antigen (PSA) < 10 ng/ml (this will be the PSA level prompting the initial prostate biopsy)
Known active invasive malignancy (except for non-melanomatous skin cancer or anaplastic thyroid cancer; the presence of prostate cancer confined to the prostate with a prostate-specific antigen [PSA] =< 1 ng/mL for more than 6 months also is allowed)
Prostate-specific antigen doubling time of ? 10 months and PSA > 2ng/ml.
Specific eligibility criteria for Part 2 CRPC expansion cohort: Prostate-Specific Antigen (PSA) levels >=2.0 ng/mL. Note: If PSA level has been obtained within 14 days of Screening, this test does not need to be repeated and the result previously obtained may be used for the Screening value.
Serum prostate-specific antigen (PSA) ? 15ng/mL.
Patients with a prostate serum antigen (PSA), equal to, or more than, 5 ng/mL.
Another primary malignancy that has not been in remission for at least 2 years; non-melanoma skin cancer, intraepithelial carcinoma of the cervix, or prostate cancer with a current prostate specific antigen (PSA) =< 0.1 ng/mL is allowed
Prostate-specific antigen (PSA) < 20 ng/dl
Serum PSA (Prostate specific antigen) progression defined as 2 subsequent increases in PSA over a previous reference value (a minimum of 2 ng/mL [?g/L]) OR
Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry
Prostate specific antigen (PSA) > 1 ng/ml, unless anaplastic features are present
Serum prostate specific antigen (PSA) < 10 ng/mL            \r\n* NOTE: baseline PSA for determination of eligibility must be measured after discontinuation of any 5-alpha reductase inhibitors
serum prostate specific antigen (PSA) ?0.5 ng/mL and ?10 ng/mL;
Have abnormal digital rectal examination, or abnormal prostate specific antigen (> 4.0 ng/ml), or obstructing prostate, or biopsy proven prostate cancer
Had a second malignancy within the previous 5 years, except for basal cell carcinoma, cervical intra-epithelial neoplasia or treated prostate cancer with a prostate-specific antigen (PSA) of <2.0 ng/mL;
Measurable disease on computed tomography (CT) or evaluable disease with an elevated prostate specific antigen (PSA)
Scheduled TRUS-guided biopsy because of clinically suspected prostate cancer (abnormal serum prostate-specific antigen [PSA] level and/or abnormal digital rectal examination)
Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or
Serum prostate specific antigen equal to or less than 10 ng/mL
Prostate-specific antigen (PSA) level of 0.1 - 50 ng/dl
Prostate-specific antigen (PSA) >= 0.2 ng/ml
Diagnostic prostate specific antigen (PSA) =< 10 ng/ml
Post-operative prostate-specific antigen (PSA) < 0.2 ng/mL by 120 days after prostatectomy
Detectable prostate-specific antigen (PSA)
Prostate-specific antigen (PSA) >= 0.1 ng/ml at time of enrollment.
With a suspicion (elevated prostate specific antigen [PSA] and/or abnormal digital rectal exam)/diagnosis of prostate cancer
Prostate specific antigen (PSA) measurement =< 42 days prior to study enrollment
Serum prostate specific antigen (PSA) =< 20 ng/ml within 3 months of study enrollment
Patients with known or suspected prostate disease based on clinical data will be included in the study; patients with intermediate to high grade prostate cancer (Gleason’s score >= 7 and prostate-specific antigen [PSA] of > 10ng/dl) will be referred from the outpatient clinics after evaluation by the treating physicians
Having elevated prostate specific antigen (PSA) (> 2.5 ng/ml) and no palpable nodule on digital rectal exam (DRE)
Prostate-specific antigen (PSA) within 4 months prior to study consent or within 30 days after study consent < 10 ng/mL
Patient has suspected recurrence based on biochemical data (prostate-specific antigen [PSA] > 2 ng/mL)
Prostate specific antigen (PSA) < 10 ng/mL
Patient has suspected recurrence based on biochemical data (prostate specific antigen [PSA] > 2 ng/mL)
For prostate cancer patients, prostate specific antigen (PSA) > 5
A rise in prostate-specific antigen (minimal value 2 ng/milliliter (mL); ?3 consecutive rising values)
Prostate-specific antigen (PSA) < 50 ng/mL